Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from Open Orphan Plc ( (GB:HVO) ).
hVIVO plc has announced that it will release a trading update for the year ended 31 December 2025 on 29 January 2026, signalling upcoming visibility on its recent financial and operational performance. The company will host a live investor presentation on the same day via the Investor Meet Company platform, open to existing and potential shareholders, underscoring its efforts to maintain active engagement with the market and enhance transparency around its growth trajectory in the human challenge trials and early-phase clinical research space.
The most recent analyst rating on (GB:HVO) stock is a Buy with a £7.00 price target. To see the full list of analyst forecasts on Open Orphan Plc stock, see the GB:HVO Stock Forecast page.
Spark’s Take on GB:HVO Stock
According to Spark, TipRanks’ AI Analyst, GB:HVO is a Outperform.
Open Orphan Plc’s overall stock score is driven by strong financial performance and attractive valuation. The company’s robust revenue growth and low leverage position it well in the biotechnology sector. While technical indicators show bullish momentum, the stock is trading below key moving averages, suggesting potential resistance. The low P/E ratio and reasonable dividend yield enhance its attractiveness to value and income investors.
To see Spark’s full report on GB:HVO stock, click here.
More about Open Orphan Plc
hVIVO plc is a full-service early phase contract research organisation (CRO) and the global leader in human challenge clinical trials, providing end-to-end clinical development services to a broad biopharma client base, including seven of the world’s ten largest pharmaceutical companies. The company specialises in infectious and respiratory disease studies from its large quarantine facility in London, supported by its hLAB virology and immunology labs, a 120-bed early-phase operation in Germany via subsidiary CRS, and consulting and biometry services through Venn Life Sciences, offering integrated solutions from preclinical work through Phase II and outpatient Phase III trials, alongside patient recruitment via FluCamp.
Average Trading Volume: 4,631,137
Technical Sentiment Signal: Sell
Current Market Cap: £40.53M
For detailed information about HVO stock, go to TipRanks’ Stock Analysis page.